Notify me when SAMLYN CAPITAL, LLC files a new Schedule 13D/G report.
⭐ Subscribe ⭐| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| PCT | PureCycle Technologies, Inc. | Common Stock, par value $0.001 per share | 7.2% | $179M | -$40.2M | 13.6M | -18.3% | Samlyn Capital, LLC | 30 Sep 2025 |
| VINP | Vinci Partners Investments Ltd. | Class A Common Shares, par value US$0.00005 per share | 4.8% | $24.1M | -$36.1K | 2.36M | -0.15% | SAMLYN CAPITAL, LLC | 31 Mar 2025 |
| INZY | Inozyme Pharma, Inc. | Common Stock, par value $0.0001 per share | 0% | $0 | 0 | Samlyn Capital, LLC | 31 Dec 2024 | ||
| CRVS | Corvus Pharmaceuticals, Inc. | Common Stock, par value $0.0001 per share | 0% | $0 | -$22M | 0 | -100% | SAMLYN CAPITAL, LLC | 30 Jun 2025 |
| NKTR | Nektar Therapeutics | Common Stock, $0.0001 par value | 0% | $0 | -$4.74M | 0 | -100% | SAMLYN CAPITAL, LLC | 31 Mar 2025 |
| Sym | Target | Class | Ownership | Change | Current Shares | Change | Value | Reporting name | Form | Report Period | Filing Date |
|---|